Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $62

Benzinga Newsdesk www.benzinga.com Positive 89.7%

Neg 0% Neu 0% Pos 89.7%

Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $60 to $62.